Oncogene DEK is highly expressed in lung cancerous tissues and positively regulates cell proliferation as well as invasion
- Authors:
- Published online on: April 5, 2018 https://doi.org/10.3892/ol.2018.8436
- Pages: 8573-8581
-
Copyright: © Zhou et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
Abstract
Introduction
Lung cancer is the most prevalent type of cancer in the world. According to the World Health Organization (WHO), about 1.59 million cases of lung cancer-related deaths were recorded worldwide in 2012; and among those, 597 thousand cases took place in China. As a populated country with lots of risk factors such as smoking and air pollution, medical care departments in China is facing with a growing burden of cancer treatment. Therefore, it is crucial to uncover the mechanism of lung cancer formation and thus develop new biomarkers for the detection and treatment of the disease. DEK is an ubiquitous protein in multicellular organisms as well as in some unicellular organisms (1). It was originally discovered as a fusion protein with CAN nucleoprotein in a subtype of acute myeloid leukemia in 1992 (2). Recent findings showed that DEK may act as an oncoprotein during tumor formation, because of its active role in regulating cell proliferation, differentiation, migration, apoptosis, senescence, self-renewal and DNA repairing (3). Meanwhile, it has been found that DEK is over-expressed in various malignant tumor cells, such as neuroendocrine prostate cancer cells, gastric adenocarcinoma cells, colorectal cancer cells, breast cancer cells, bladder cancer cells, human hepatocellular carcinoma cells and so on, while it remains in a low level or is even undetectable in quiescent and terminally differentiated cells (4–16). Over-expression of DEK boosts proliferation and transformation of epithelial cells, promotes tumor growth and metastasis of breast cancer cells, while it inhibits normal cell differentiation, suppresses p53 pathway-induced apoptosis and acts as a senescence inhibitor with E6 and E7 oncogene (17,18). DEK depletion, on the other hand, may trigger cell apoptosis or senescence (19–23), and also sensitize cells to chemotherapy or genotoxic agents (9,23–26). These facts demonstrate the potential applications of DEK as a tumor diagnostic biomarker and also as a therapeutic target.
This study focused on the poorly understood function of DEK in lung cancer cells, and discovered the clinical pathological significance of DEK in lung cancer detection and treatment.
Materials and methods
Clinical samples and ethics statement
In this study, 81 specimens of surgically resected lung tumors as well as corresponding adjacent precancerous tissue (with 30 cm distance from the tumor's edge) and/or normal tissues (with 50 cm distance from the tumor's edge) were collected at the Fourth Military Medical University Affiliated Tangdu Hospital and the General Hospital of People's Liberation Army from December 2010 to November 2014 after receiving the patients' informed consent and the approval of hospital authorities. None of the patients received radiotherapy or chemotherapy prior to the pulmonary surgery. After surgical removal, all of the samples were immediately snap-frozen in liquid nitrogen and stored at −80°C for RNA (29 cases) and protein analyses. All cancerous tissues were primary tumors according to the International Union against Cancer guidelines. The Beijing Jiaotong University Institutional Review Board approved the present study.
Cell cultures, siRNAs and plasmids
A549 cell line was obtained from American Type Culture Collection (Manassas, VA, USA). Cells were cultured in Dulbecco's Modified Eagle Medium (DMEM; Invitrogen; Thermo Fisher Scientific, Inc., Waltham, MA, USA) with 10% fetal bovine serum (FBS) and were passaged every 3 days using 0.25% trypsin (Merck KGaA, Darmstadt, Germany). The siRNA targeting DEK CDS region was synthesized by Invitrogen, and it was transfected into A549 cells using Lipofectamine 3000 (Invitrogen; Thermo Fisher Scientific, Inc.) according to the manufacturer's protocol. Sequences of the siRNAs are listed (Table I). The pcDNA3.1-hDEK plasmid was constructed using the pcDNA3.1 (−) plasmid and the DEK CDS sequence with a 6xCAT Histidine Tag at its N-terminal. A corresponding negative control plasmid was constructed with an EGFP CDS sequence replacing the His-DEK, and it acted as a positive control for the transfection.
RNA extraction and reverse transcription-PCR
Total RNA was extracted from the lung tumor and matched non-tumorous tissues using Trizol reagent (Invitrogen; Thermo Fisher Scientific, Inc.). A total of 1.5 µg mRNA aliquot from each sample were reverse transcribed to double-stranded cDNAs using Go Script™ Reverse Transcription System (Promega Corporation, Madison, WI, USA) with the final volume of 20 µl. Quantitative reverse transcription-PCR (qRT-PCR) was performed using Super Real PreMix Plus (SYBR Green; Tiangen Biotech Co., Ltd., Beijing, China) and Light Cycler 480 (Roche Diagnostics, Indianapolis, IN, USA) according to the manufacturer's protocol. cDNAs were diluted into quarters and 1 µl of diluted cDNAs were added into the reaction mix with the final volume of 20 µl. Reaction conditions were as followed: 95°C 15 min; followed by 40 cycles of 95°C 10 sec, 60°C 20 sec (signal acquisition). Experiment was performed in triplicates and the fold change of each gene was calculated using the 2−ΔΔCt method. Primers used in this experiment are listed (Table II).
Immunohistochemistry
Immunohistochemistry (IHC) was performed on formalin-fixed paraffin-embedded tumor tissues, which were sectioned (4 mm) and mounted on polylysine-coated slides. The sections were deparaffinized in xylene and then rehydrated in decreasing concentrations of ethanol (100, 95, 80 and 70%, respectively). Antigen was retrieved by incubating sections with sodium citrate buffer (pH 6.0) for 10 min in the microwave. Slides were incubated with 3% (v/v) H2O2 for 15 min to inhibit endogenous peroxidase activity. To further reduce non-specific background staining, sections were incubated in 20% (v/v) normal goat serum for 20 min and were then incubated with the DEK-specific primary rabbit antibody (dilution 1:300; ProteinTech Group, Inc., Chicago, IL, USA) at 37°C for 2 h. The Goat anti Rabbit IgG/HRP polymer conjugate (OriGene Technologies, Inc., Rockville, MD, USA) were added to the sections and incubated at 37°C for 15 min according to the manufacturer's protocol. Between each aforementioned steps, the sections were washed with phosphate-buffered saline (PBS) for 6 min. Immunostaining was visualized by developing the slides in diaminobenzidin (DAB). The sections were counterstained with hematoxylin for 4 sec, dehydrated and mounted. Each slide was observed under the microscope at magnification, ×400. Semi-quantitative percentage score was given according to the nuclear staining of cells from five views. Percentage scores were assigned as follows: 0–5%: negative (−), 6–25%: weak positive (+), 26–50%: positive (++), 51–100%: strong positive (+++).
Western blotting analysis
Cells were trypsinized after transfection for 48 h using 0.25% trypsin (Merck KGaA), then lysed using 1X SDS-PAGE loading buffer [0.045 mol/l Tris-HCl (pH 6.8); 10% glycerin, 1% SDS; 0.004% bromophenol blue; 0.5 mol/l DTT; with a final concentration of 200 µl loading buffer every 1×106 cells]. 30 µl of each sample was loaded and separated in a 12% SDS-polyacrylamide gel by electrophoresis. Proteins were transferred onto nitrocellulose filter membrane (NC membrane; Pall Life Sciences, Port Washington, NY, USA) and incubated in the following reagents: 5% non-fat milk (4°C, over-night); primary antibodies (DEK rabbit polyclonal antibody: 1:1,000, ProteinTech Group, Inc.; β-actin mouse monoclonal antibody: 1:1,000, OriGene Technologies, Inc.; His mouse monoclonal antibody: 1:500, OriGene Technologies, Inc.); secondary antibodies (Peroxidase-Conjugated AffiniPure Goat anti-mouse IgG: 1:2,000, OriGene Technologies, Inc.; or Peroxidase-Conjugated AffiniPure Goat anti-rabbit IgG: 1:2,000, OriGene Technologies, Inc.; 37°C, 1 h). After each aforementioned incubation step, the membrane was washed in TBST buffer for 3 times, 5 min each time. So were the reagent and antibodies diluted in TBST buffer. After the final washing step, bound proteins were visualized using ECL (Thermo Fisher Scientific, Inc.) and X-ray film (Fujifilm, Shanghai, China). The relative expression level of each gene was analyzed based on β-actin as the loading control.
MTT assay
A549 cells were planted on 96-well plate before transfection, with 100 µl of medium, 1,000 cells per well. 10 µl MTT reagent was added to wells 24, 48, 72 and 96 h after transfection, and the plate was incubated in 37°C for 4 h. After discarding the media, 100 µl of DMSO was added to dissolve the MTT formazan in each well. The plate was incubated in 37°C for another 4 h and the optical density was read using a wavelength of 570 nm. Each test was performed in triplicates.
Colony formation assay
Cells were replanted in 6-well cell culture dishes 48 h after transfection with 1,000 cells per well. Medium was renewed every two days. 7 days after transfection, colonies were stained by 0.1% crystal violet (Beyotime Institute of Biotechnology, Haimen, China), and visible colonies were counted. Each test was performed in triplicates.
Matrigel cell invasion assay
48 h after transfection, 10,000 cells were replanted onto the upper membrane of transwell chamber (EMD Millipore, Billerica, MA, USA) covered with Matrigel (BD Biosciences, Franklin Lakes, NJ, USA) according to the manufacturer's protocol. The upper chamber contained 200 µl of DMEM, and the lower chamber contained 600 µl of DMEM with 10% FBS as chemoattractant. 24 h after incubation, the chamber was washed with PBS and cells on the upper membrane were gently removed. Then the membrane was stained with crystal violet (Beyotime Institute of Biotechnology, Haimen, China). Number of migrated cells were counted under the microscope with magnification, ×100, 5 randomly selected areas on each membrane were counted.
Statistical analysis
All data were analyzed using SPSS version 20. Immunohistochemistry results were analyzed using the chi-squared tests, and all other results were analyzed using the unpaired, two-tailed Student's t-tests. All statistical data were presented as means ± standard deviation. A test with a P<0.05 was considered to indicate a statistically significant difference.
Results
Over-expression of DEK mRNA detected in lung cancerous tissues
Real-time quantitative RT-PCR (qRT-PCR) was performed in 29 cases of lung cancerous tissues paired with non-cancerous counterparts. DEK-over expression means that in tumor samples the DEK is more expressed than in the adjacent normal tissue samples. As shown in Table III, DEK mRNA was over-expressed in 15 out of 29 (51.7%) cases of lung cancerous tissues paired with normal tissues. Among those, 14 cases (48.3%) showed over two-fold up-regulation of DEK mRNA level, 9 cases (31.0%) showed over five-fold up-regulation of DEK mRNA level. In adenocarcinoma tissues, 7 out of 8 cases (87.5%) showed over-expression of DEK mRNA, which was significantly higher than those of other histopathological types. However, no correlation between the over-expression of DEK mRNA and patient's age, gender, pleural invasion status as well as TMN stage was found (Table IV).
Over-expression of DEK protein detected in lung cancerous tissues
The expression level of DEK protein in lung cancerous tissues and non-cancerous counterparts were detected by IHC (Fig. 1). Among 81 cases of lung cancerous tissues, 66 cases (81.5%) showed positive staining of DEK protein, while 32 cases (39.5%) showed strong positive staining of DEK protein, which was significantly higher than those in normal tissues (Table V). However, there was no significant correlation between strong positive staining of DEK protein and clinicopathological characteristics of patients (Table VI).
Table V.Association between DEK protein expression and tissue position according to immunohistochemistry results. |
DEK depletion and over-expression in A549 lung cancer cells
To further investigate the function of DEK in lung cancer cells, siRNA as well as plasmid encoding His-tagged DEK CDS were employed respectively to down-regulate and up-regulate the expression level of DEK in A549 lung cancer cell line. The expression level of DEK mRNA and protein were analyzed by qRT-PCR and Western Blotting (WB). Results showed the expression level of DEK mRNA and protein were down-regulated by siRNA transfection; while the transfection of plasmid encoding His-tagged DEK caused DEK over-expression in A549 cells (Fig. 2).
DEK positively regulates proliferation in A549 cells
To detect whether DEK could regulate cell proliferation in lung cancer cell lines, MTT assay was performed in DEK depleted and over-expressed A549 cells. Results showed that cell proliferation was significantly restricted after day 4 in DEK depleted cells, while being significantly promoted after day 3 and day 4 in DEK over-expressed cells (Fig. 3A and B). A supplementary experiment of colony formation assay was performed and the results were in accordance with the former one. A significant decrease of colony numbers in DEK depleted cells and a significant increase of colony numbers in DEK over-expressed cells were detected (Fig. 3C-F). Both experiments manifested the positive correlation between DEK expressional level and cell proliferation, showing DEK may act as a pro-proliferation factor in A549 cells. As a chromatin associated architectural protein, DEK may play an important role in change of chromatin structure and thereby the expression of genes related to cell proliferation.
DEK positively regulates invasion of A549 cells
Matrigel invasion assay was performed to detect alterations DEK made to cell invasion. Decrease of invaded cell numbers was shown in DEK depleted A549 cells, while DEK over-expressed cells resulted in an increase of invaded cell numbers (Fig. 4). According to the results, the invasion of A549 cells was positively correlated with DEK expression.
Discussion
DEK is over-expressed in various type of malignant carcinomas, such as acute myeloid leukemia, retinoblastoma, brain malignant glioma, hepatocellular carcinoma, breast cancer, uterine cervical cancer, bladder cancer, colon cancer, colorectal cancer, gastric adenocarcinoma, oral squamous cell carcinoma, neuroendocrine prostate cancer (5–8,10–17,27). It was first discovered that DEK was over-expressed in high-grade neuroendocrine carcinoma of the lung by Shibata et al (9), yet it was only limited on the type of neuroendocrine carcinoma. Here we examined the expression level of DEK in various subtypes of lung cancer, and discovered that DEK mRNA is over-expressed in 51.7% of lung cancerous tissues. Especially, in adenocarcinoma tissues of the lung, DEK showed a significantly high over-expression rate of 87.5%. The IHC experiment showed similar results, 39.5% of lung cancerous tissues showed strong positive expression of DEK protein, while the number was only 20.5% in normal tissues. These findings gave valuable hints to the biomarker development of DEK, showing that DEK might have the potential to be applied as a diagnostic biomarker for lung cancers, especially for adenocarcinoma of the lung. However, neither of these studies demonstrated the relationship between DEK expression and patient's age, gender, or TMN stage, differentiation status of the carcinoma.
We have analyzed the expression of DEK in mRNA and protein level in lung cancer samples, not only the NSCLC samples reported in the study by Liu et al (28), which explored the role of DEK expression for the prognostic evaluation of non-small cell lung carcinoma (NSCLC). Besides, based on the previous findings, the downstream effects of aberrant DEK expressional level were analyzed using the A549 lung cancer cell line. Through silence and overexpression of DEK in A549 cells, we found that DEK could influence the proliferation and invasion of A549 tumor cells. In our study, it was discovered that the over-expression of DEK promotes cell proliferation and invasion, which was in accordance with former studies in other types of cancers (3,8,17,19). The findings support the carcinogenic role of DEK in lung cancer formation, and it could be the reason for the aberrant expressional level of DEK in lung cancerous tissues we detected earlier. On the other hand, depletion of DEK in A549 cells gave us the exact opposite story. Our study showed that DEK depletion could repress proliferation and invasion of lung tumor cells. Therefore, DEK could act as a target for lung tumor therapy applied in clinical studies. In our study, the depletion of the gene expression was accomplished by siRNA transfection, which made the therapy easier to be applied clinically.
To sum up, the present study discovered that DEK was over-expressed in lung cancerous tissues. The aberrant expression of DEK may promote cell survival and tumorigenesis. The more detailed discussion of DEK's mechanism in lung cancer formation should be done in the future studies, and clinical studies using larger groups of samples should be performed to discover the further application value of DEK as a novel biomarker.
Acknowledgements
Not applicable.
Funding
This study has been funded by the National Natural Science Foundation of China (grant no. 81201762).
Availability of data and material
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.
Author's contributions
QCZ, JY, MXQ, HHL and ZQ performed the experiments and analyzed the data. XFD contributed to the collection of human lung tissue samples and RNA extraction. LLH, HJ and HGH conceived and designed the study. QCZ and JY drafting the manuscript, which was critically revised by LLH and HGH.
Ethics approval and consent to participate
The present study was approved by the Beijing Jiaotong University Institutional Review Board. Written informed consent was obtained from all patients prior to their inclusion.
Consent for publication
Informed consent was obtained from all patients' for the publication of their data.
Competing interests
The authors declare that they have no competing interests.
References
Waldmann T, Scholten I, Kappes F, Hu HG and Knippers R: The DEK protein-an abundant and ubiquitous constituent of mammalian chromatin. Gene. 343:1–9. 2004. View Article : Google Scholar : PubMed/NCBI | |
von Lindern M, Breems D, van Baal S, Adriaansen H and Grosveld G: Characterization of the translocation breakpoint sequences of two DEK-CAN fusion genes present in t(6;9) acute myeloid leukemia and a SET-CAN fusion gene found in a case of acute undifferentiated leukemia. Genes Chromosomes Cancer. 5:227–234. 1992. View Article : Google Scholar : PubMed/NCBI | |
Vinnedge Privette LM, Kappes F, Nassar N and Wells SI: Stacking the DEK: From chromatin topology to cancer stem cells. Cell Cycle. 12:51–66. 2013. View Article : Google Scholar : PubMed/NCBI | |
Grottke C, Mantwill K, Dietel M, Schadendorf D and Lage H: Identification of differentially expressed genes in human melanoma cells with acquired resistance to various antineoplastic drugs. Int J Cancer. 88:535–546. 2000. View Article : Google Scholar : PubMed/NCBI | |
Wang X, Huang SH, Yu LQ, Liu J, Diao Y and Sun CF: Relationship between DEK oncogene expression and oral squamous cell carcinoma. Shanghai Kou Qiang Yi Xue. 23:75–79. 2014.(In Chinese). PubMed/NCBI | |
Piao J, Shang Y, Liu S, Piao Y, Cui X, Li Y and Lin Z: High expression of DEK predicts poor prognosis of gastric adenocarcinoma. Diagn Pathol. 9:672014. View Article : Google Scholar : PubMed/NCBI | |
Lin L, Piao J, Gao W, Piao Y, Jin G, Ma Y, Li J and Lin Z: DEK over expression as an independent biomarker for poor prognosis in colorectal cancer. BMC Cancer. 13:3662013. View Article : Google Scholar : PubMed/NCBI | |
Vinnedge Privette LM, McClaine R, Wagh PK, Wikenheiser-Brokamp KA, Waltz SE and Wells SI: The human DEK oncogene stimulates β-catenin signaling, invasion and mammosphere formation in breast cancer. Oncogene. 30:2741–2752. 2011. View Article : Google Scholar : PubMed/NCBI | |
Shibata T, Kokubu A, Miyamoto M, Hosoda F, Gotoh M, Tsuta K, Asamura H, Matsuno Y, Kondo T, Imoto I, et al: DEK oncoprotein regulates transcriptional modifiers and sustains tumor initiation activity in high-grade neuroendocrine carcinoma of the lung. Oncogene. 29:4671–4681. 2010. View Article : Google Scholar : PubMed/NCBI | |
Wu Q, Li Z, Lin H, Han L, Liu S and Lin Z: DEK overexpression in uterine cervical cancers. Pathol Int. 58:378–382. 2008. View Article : Google Scholar : PubMed/NCBI | |
Orlic M, Spencer CE, Wang L and Gallie BL: Expression analysis of 6p22 genomic gain in retinoblastoma. Genes Chromosomes Cancer. 45:72–82. 2006. View Article : Google Scholar : PubMed/NCBI | |
Carro MS, Spiga FM, Quarto M, Di Ninni V, Volorio S, Alcalay M and Müller H: DEK Expression is controlled by E2F and deregulated in diverse tumor types. Cell Cycle. 5:1202–1207. 2006. View Article : Google Scholar : PubMed/NCBI | |
Sanchez-Carbayo M, Socci ND, Lozano JJ, Li W, Charytonowicz E, Belbin TJ, Prystowsky MB, Ortiz AR, Childs G and Cordon-Cardo C: Gene discovery in bladder cancer progression using cDNA microarrays. Am J Pathol. 163:505–516. 2003. View Article : Google Scholar : PubMed/NCBI | |
Larramendy ML, Niini T, Elonen E, Nagy B, Ollila J, Vihinen M and Knuutila S: Overexpression of translocation-associated fusion genes of FGFRI, MYC, NPMI, and DEK, but absence of the translocations in acute myeloid leukemia. A microarray analysis. Haematologica. 87:569–577. 2002.PubMed/NCBI | |
Kroes RA, Jastrow A, McLone MG, Yamamoto H, Colley P, Kersey DS, Yong VW, Mkrdichian E, Cerullo L, Leestma J and Moskal JR: The identification of novel therapeutic targets for the treatment of malignant brain tumors. Cancer Lett. 156:191–198. 2000. View Article : Google Scholar : PubMed/NCBI | |
Kondoh N, Wakatsuki T, Ryo A, Hada A, Aihara T, Horiuchi S, Goseki N, Matsubara O, Takenaka K, Shichita M, et al: Identification and characterization of genes associated with human hepatocellular carcinogenesis. Cancer Res. 59:4990–4996. 1999.PubMed/NCBI | |
Wise-Draper TM, Mintz-Cole RA, Morris TA, Simpson DS, Wikenheiser-Brokamp KA, Currier MA, Cripe TP, Grosveld GC and Wells SI: Overexpression of the cellular DEK protein promotes epithelial transformation in vitro and in vivo. Cancer Res. 69:1792–1799. 2009. View Article : Google Scholar : PubMed/NCBI | |
Wise-Draper TM, Allen HV, Thobe MN, Jones EE, Habash KB, Münger K and Wells SI: The human DEK proto-oncogene is a senescence inhibitor and an upregulated target of high-risk human papillomavirus E7. J Virol. 79:14309–14317. 2005. View Article : Google Scholar : PubMed/NCBI | |
Wise-Draper TM, Allen HV, Jones EE, Habash KB, Matsuo H and Wells SI: Apoptosis inhibition by the human DEK oncoprotein involves interference with p53 functions. Mol Cell Biol. 26:7506–7519. 2016. View Article : Google Scholar | |
Liu K, Feng T, Liu J, Zhong M and Zhang S: Silencing of the DEK gene induces apoptosis and senescence in CaSki cervical carcinoma cells via the up-regulation of NF-κB p65. Biosci Rep. 32:323–332. 2012. View Article : Google Scholar : PubMed/NCBI | |
Kim DW, Chae JI, Kim JY, Pak JH, Koo DB, Bahk YY and Seo SB: Proteomic analysis of apoptosis related proteins regulated by proto-oncogene protein DEK. J Cell Biochem. 106:1048–1059. 2009. View Article : Google Scholar : PubMed/NCBI | |
Waldmann T, Eckerich C, Baack M and Gruss C: The ubiquitous chromatin protein DEK alters the structure of DNA by introducing positive supercoils. J Biol Chem. 277:24988–24994. 2002. View Article : Google Scholar : PubMed/NCBI | |
Kavanaugh GM, Wise-Draper TM, Morreale RJ, Morrison MA, Gole B, Schwemberger S, Tichy ED, Lu L, Babcock GF, Wells JM, et al: The human DEK oncogene regulates DNA damage response signaling and repair. Nucleic Acids Res. 39:7465–7476. 2011. View Article : Google Scholar : PubMed/NCBI | |
Kappes F, Fahrer J, Khodadoust MS, Tabbert A, Strasser C, Mor-Vaknin N, Moreno-Villanueva M, Bürkle A, Markovitz DM and Ferrando-May E: DEK is a poly(ADP-ribose) acceptor in apoptosis and mediates resistance to genotoxic stress. Mol Cell Biol. 28:3245–3257. 2008. View Article : Google Scholar : PubMed/NCBI | |
Khodadoust MS, Verhaegen M, Kappes F, Riveiro-Falkenbach E, Cigudosa JC, Kim DS, Chinnaiyan AM, Markovitz DM and Soengas MS: Melanoma proliferation and chemoresistance controlled by the DEK oncogene. Cancer Res. 69:6405–6413. 2009. View Article : Google Scholar : PubMed/NCBI | |
Martinez-Useros J, Rodriguez-Remirez M, Borrero-Palacios A, Moreno I, Cebrian A, del Pulgar Gomez T, del Puerto-Nevado L, Vega-Bravo R, Puime-Otin A, Perez N, et al: DEK is a potential marker for aggressive phenotype and irinotecan-based therapy response in metastatic colorectal cancer. BMC Cancer. 14:9652014. View Article : Google Scholar : PubMed/NCBI | |
Lin D, Dong X, Wang K, Wyatt AW, Crea F, Xue H, Wang Y, Wu R, Bell RH, Haegert A, et al: Identification of DEK as a potential therapeutic target for neuroendocrine prostate cancer. Oncotarget. 6:1806–1820. 2015. View Article : Google Scholar : PubMed/NCBI | |
Liu X, Qi D, Qi J, Mao Z, Li X, Zhang J, Li J and Gao W: Significance of DEK overexpression for the prognostic evaluation of non-small cell lung carcinoma. Oncol Rep. 35:155–162. 2016. View Article : Google Scholar : PubMed/NCBI |